在三名淋巴瘤患者中,在使用bendamustine后发生心房动
Najwa Al Himali1, Khalil Al Farsi2
1Department of Pharmacy, Sultan Qaboos University Hospital, Muscat, Oman.
概括
化学疗法药物本达穆斯丁 (Bendamustine) 可能在淋巴瘤患者治疗开始后不久意外引起心房动 (AF). 需要进一步的研究来了解这种心脏副作用,并确定有风险的个体.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 班达穆斯丁是一种广泛用于各种淋巴瘤的化疗剂.
- 心脏毒性不是 bendamustine 的常见副作用.
研究的目的:
- 在淋巴瘤患者中报告三例动,发生在本达穆斯丁开始治疗后不久.
- 要突出与达穆斯丁治疗相关的潜在,以前报告不足的心脏不良事件.
主要方法:
- 一系列病例描述了三名患有不同淋巴瘤亚型 (MZL,DLBCL,cHL) 的患者.
- 在开始使用70-90mg/m2.2的达穆斯丁后1-2天内观察AF的发展.
- 治疗包括抗失常药物和抗凝药.
主要成果:
- 这三名患者在接受了bendamustine治疗后都出现了新发性心房动 (AF).
- 尽管治疗,但AF在患者中仍然存在,需要进行心脏病随访.
- 在大多数情况下,由于心脏事件,淋巴瘤治疗发生了改变.
结论:
- 班达穆斯丁可能与诱导心房的风险有关,即使在没有传统心脏风险因素的患者中也是如此.
- 需要进一步的研究来证实这种关联,阐明机制,并确定易受感染的患者.
- 这一发现需要在达穆斯丁治疗期间对心脏事件提高警.
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
990
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
990
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
847
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
847
Myocarditis III: Medical Management
16
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
16
Heart Failure Drugs: Inotropic Agents
722
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
722


